Magnus Sellstedt

Dr. Magnus Sellstedt

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2012 in Journal of the American Chemical Society
Verified
Journal Article
Open access
IHIstvan Horvath
Istvan Horvath
CWChristoph F. Weise
Christoph F. Weise
EAEmma K. Andersson
Emma K. Andersson
ECErik Chorell
Erik Chorell
MSMagnus Sellstedt
Magnus Sellstedt
PWPernilla Wittung-Stafshede
Pernilla Wittung-Stafshede
Small organic molecules that inhibit functional bacterial amyloid fibers, curli, are promising new antibiotics. Here we investigated the mechanism by which the ring-fused 2-pyridone FN075 inhibits fibrillation of the curli protein CsgA. Using a variety of biophysical techniques, we found that FN075 promotes CsgA to form off-pathway, non-amyloidogenic oligomeric species. In light of the generic properties of amyloids, we tested whether FN075 would also affect the fibrillation reaction of human α-synuclein, an amyloid-forming protein involved in Parkinson’s disease. Surprisingly, FN075 stimulates α-synuclein amyloid fiber formation as measured by thioflavin T emission, electron microscopy (EM), and atomic force microscopy (AFM). NMR data on 15N-labeled α-synuclein show that upon FN075 addition, α-synuclein oligomers with 7 nm radius form in which the C-terminal 40 residues remain disordered and solvent exposed. The polypeptides in these oligomers contain β-like secondary structure, and the oligomers are detectable by AFM, EM, and size-exclusion chromatography (SEC). Taken together, FN075 triggers oligomer formation of both proteins: in the case of CsgA, the oligomers do not proceed to fibers, whereas for α-synuclein, the oligomers are poised to rapidly form fibers. We conclude that there is a fine balance between small-molecule inhibition and templation that depends on protein chemistry.

1 October 2013 in Chemistry & Biology
Verified
Journal Article
Closed access
EAEmma K. Andersson
Emma K. Andersson
CBChristoffer Bengtsson
Christoffer Bengtsson
MEMargery L. Evans
Margery L. Evans
ECErik Chorell
Erik Chorell
MSMagnus Sellstedt
Magnus Sellstedt
MCMatthew Chapman
Matthew Chapman

1 November 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
VÅVeronica Åberg
Veronica Åberg
MSMagnus Sellstedt
Magnus Sellstedt
MHMattias Hedenström
Mattias Hedenström
JPJerome S. Pinkner
Jerome S. Pinkner
SHScott J. Hultgren
Scott J. Hultgren
FAFredrik Almqvist
Fredrik Almqvist

9 February 2013 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
IHIstvan Horvath
Istvan Horvath
MSMagnus Sellstedt
Magnus Sellstedt
CWChristoph Weise
Christoph Weise
LNLina-Maria Nordvall
Lina-Maria Nordvall
GPG. Krishna Prasad
G. Krishna Prasad
PWPernilla Wittung-Stafshede
Pernilla Wittung-Stafshede

24 September 2010 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
MSMagnus Sellstedt
Magnus Sellstedt
ANAnders Nyberg
Anders Nyberg
ERErik Rosenbaum
Erik Rosenbaum
PEPatrik Engström
Patrik Engström
MWMalin Wickström
Malin Wickström
FAFredrik Almqvist
Fredrik Almqvist

18 November 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
MSMagnus Sellstedt
Magnus Sellstedt
MSMelanie Schwalfenberg
Melanie Schwalfenberg
SZSlava Ziegler
Slava Ziegler
AAAndrey P. Antonchick
Andrey P. Antonchick
HWHerbert Waldmann
Herbert Waldmann
Asymmetric trienamine catalysis was used to synthesize cytochalasin B-like compounds and inhibition of glucose uptake in cancer cells was demonstrated.